Strategic Plan 2019

Our latest strategic plan is built on three pillars — ImmunotherapyInvestment, and Data. Targeting our efforts in these three areas will transform how multiple myeloma is treated and ultimately cured.

In 2018, MMRF Founder and Chief Mission Officer, Kathy Giusti lead the development of our three-year Strategic Plan to reflect her vision of accelerating a cure for every myeloma patient. The MMRF team performed a comprehensive analysis of the research landscape, studied every drug and research portfolio in the field of myeloma. We consulted with the best and brightest clinicians, researchers, pharmaceutical companies, and data experts in myeloma and with others outside the myeloma community. Most importantly, we listened and heard every idea from myeloma patients about how we can improve their care and their every hope for today and their future.

The result is an innovative three-year strategic plan with profound potential to revolutionize how multiple myeloma is treated and eventually cured. Together, this will enable us to usher in a new era of discoveries that will deliver the breakthrough treatments patients deserve.

Our plan focuses on three critical areas: 

Immunotherapy. Immunotherapy trains and directs the body’s natural immune system to attack cancer cells. In the last few years alone, more than 2,000 new immunotherapy agents have entered development. Unfortunately, few are focused on multiple myeloma. The ones that are don’t work for every patient. We are focusing on several specific types of immunotherapy that show promise for myeloma, including chimeric antigen receptor T-cell (CAR-T) therapy and monoclonal antibodies.

Advancing immune therapy in multiple myeloma will require detailed knowledge of patient immunity and how it changes throughout the course of the disease and treatment.  In 2019, we launched the Immune Atlas, an exciting precision medicine initiative designed to comprehensively gather this information. The Immune Atlas will be a detailed map of the immune landscape in myeloma. We will integrate this immune data with genomic and patient health information to answer critical immune-related questions relating to myeloma. Read more.

Investment. In 2019, we created the Myeloma Investment Fund (MIF), a $50 million self-sustaining venture philanthropy fund designed to accelerate bringing new therapies to myeloma patients. The MIF identifies and invests in the most promising biotechnology companies whose work is geared toward transforming myeloma treatment.  As these investments generate returns, we will reinvest 100% directly back into research for new treatments. Our first two investments are with NexImmune and Tidal Therapeutics. Read more.

Data. Multiple myeloma is an incredibly diverse disease at the genetic level. Because every patient is different, we will need a multitude of drugs to effectively treat and cure every patient. Each day, patients call us asking what treatment is right for their specific myeloma subtype. The answer lies in the data. In 2019, we launched the MMRF CureCloud®, the first, largest, and most comprehensive data bub—designed to speed the delivery of precision-based treatment to every multiple myeloma patient. The CureCloud is a bold new initiative which will integrate vast amounts of health data from thousands of multiple myeloma patients and make this data available to Researchers, to help discover new targets for myeloma and form hypotheses for clinical trials and to patients and their physicians, so that they can make more informed data-driven decisions. A critical component of the CureCloud is a Direct-to-Patient Registry where patients can share their data safely and securely from their own computer or phone. Read more.

We invite you to watch an inspiring video from MMRF Founder and Chief Mission Officer, Kathy Giusti and our partners demonstrating how we will execute on this strategic plan.